Moreover, activating HRAS mutations were recently detected in HCC developed in mice with non-alcoholic fatty liver disease [21], which is increasingly recognized as promotor of hepatocarcinogenesis [1]. The gene discussed is HRAS; the disease is metabolic dysfunction-associated steatotic liver disease.